Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and integrating instrumentation… Read more
Stratec SE (STSEY) - Net Assets
Latest net assets as of September 2025: $240.08 Million USD
Based on the latest financial reports, Stratec SE (STSEY) has net assets worth $240.08 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($431.24 Million) and total liabilities ($191.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $240.08 Million |
| % of Total Assets | 55.67% |
| Annual Growth Rate | 57.44% |
| 5-Year Change | 40.56% |
| 10-Year Change | 86.16% |
| Growth Volatility | 23981.6 |
Stratec SE - Net Assets Trend (2002–2024)
This chart illustrates how Stratec SE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Stratec SE (2002–2024)
The table below shows the annual net assets of Stratec SE from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $242.53 Million | +3.95% |
| 2023-12-31 | $233.33 Million | +3.62% |
| 2022-12-31 | $225.18 Million | +9.44% |
| 2021-12-31 | $205.76 Million | +19.25% |
| 2020-12-31 | $172.54 Million | +8.51% |
| 2019-12-31 | $159.01 Million | +4.47% |
| 2018-12-31 | $152.20 Million | -3.57% |
| 2017-12-31 | $157.84 Million | +9.82% |
| 2016-12-31 | $143.72 Million | +10.32% |
| 2015-12-31 | $130.28 Million | +16.27% |
| 2014-12-31 | $112.05 Million | +15.30% |
| 2013-12-31 | $97.18 Million | +5.65% |
| 2012-12-31 | $91.98 Million | +10.52% |
| 2011-12-31 | $83.23 Million | +15.79% |
| 2010-12-31 | $71.88 Million | +21.24% |
| 2009-12-31 | $59.29 Million | +18.81% |
| 2008-12-31 | $49.90 Million | +2.73% |
| 2007-12-31 | $48.58 Million | +21.03% |
| 2006-12-31 | $40.13 Million | +27.32% |
| 2005-12-31 | $31.52 Million | +103.80% |
| 2004-12-31 | $15.47 Million | +20.17% |
| 2003-12-31 | $12.87 Million | +115147.08% |
| 2002-12-31 | $11.17K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Stratec SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.16 Million | 5.01% |
| Other Components | $230.38 Million | 94.99% |
| Total Equity | $242.53 Million | 100.00% |
Stratec SE Competitors by Market Cap
The table below lists competitors of Stratec SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lam Dong Mineral and Building Material JSC
VN:LBM
|
$48.58 Million |
|
Oncopeptides AB (publ)
PINK:ONPPF
|
$48.58 Million |
|
Precise Corporation Public Company Limited
BK:PCC
|
$48.59 Million |
|
Gevelot
PA:ALGEV
|
$48.61 Million |
|
AudioEye Inc
NASDAQ:AEYE
|
$48.56 Million |
|
Prevas AB Series B
LSE:0H2J
|
$48.55 Million |
|
209640
KQ:209640
|
$48.54 Million |
|
Jagran Prakashan Limited
NSE:JAGRAN
|
$48.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stratec SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 233,326,000 to 242,533,000, a change of 9,207,000 (3.9%).
- Net income of 16,021,000 contributed positively to equity growth.
- Dividend payments of 6,687,000 reduced retained earnings.
- Other comprehensive income decreased equity by 20,222,000.
- Other factors increased equity by 20,095,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $16.02 Million | +6.61% |
| Dividends Paid | $6.69 Million | -2.76% |
| Other Comprehensive Income | $-20.22 Million | -8.34% |
| Other Changes | $20.09 Million | +8.29% |
| Total Change | $- | 3.95% |
Book Value vs Market Value Analysis
This analysis compares Stratec SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 29003.90x to 8.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $0.00 | $6.70 | x |
| 2003-12-31 | $0.26 | $6.70 | x |
| 2004-12-31 | $0.31 | $6.70 | x |
| 2005-12-31 | $0.60 | $6.70 | x |
| 2006-12-31 | $0.71 | $6.70 | x |
| 2007-12-31 | $0.85 | $6.70 | x |
| 2008-12-31 | $0.88 | $6.70 | x |
| 2009-12-31 | $1.04 | $6.70 | x |
| 2010-12-31 | $1.23 | $6.70 | x |
| 2011-12-31 | $1.42 | $6.70 | x |
| 2012-12-31 | $1.57 | $6.70 | x |
| 2013-12-31 | $1.65 | $6.70 | x |
| 2014-12-31 | $1.89 | $6.70 | x |
| 2015-12-31 | $2.19 | $6.70 | x |
| 2016-12-31 | $2.41 | $6.70 | x |
| 2017-12-31 | $2.63 | $6.70 | x |
| 2018-12-31 | $2.53 | $6.70 | x |
| 2019-12-31 | $2.64 | $6.70 | x |
| 2020-12-31 | $2.84 | $6.70 | x |
| 2021-12-31 | $3.38 | $6.70 | x |
| 2022-12-31 | $3.70 | $6.70 | x |
| 2023-12-31 | $3.84 | $6.70 | x |
| 2024-12-31 | $0.80 | $6.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stratec SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.61%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.22%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.84x
- Recent ROE (6.61%) is below the historical average (487.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 9947.18% | 3.95% | 1313.10x | 1.92x | $1.11 Million |
| 2003 | 13.08% | 5.13% | 1.38x | 1.85x | $396.86K |
| 2004 | 17.96% | 7.09% | 1.53x | 1.66x | $1.23 Million |
| 2005 | 14.00% | 9.11% | 1.11x | 1.38x | $1.26 Million |
| 2008 | 20.02% | 14.80% | 0.97x | 1.40x | $5.00 Million |
| 2009 | 19.69% | 14.67% | 0.93x | 1.45x | $5.74 Million |
| 2010 | 18.14% | 12.22% | 1.08x | 1.38x | $5.85 Million |
| 2011 | 18.36% | 12.51% | 1.10x | 1.33x | $6.96 Million |
| 2012 | 15.19% | 11.41% | 1.00x | 1.32x | $4.77 Million |
| 2013 | 15.93% | 12.10% | 1.09x | 1.21x | $5.76 Million |
| 2014 | 17.64% | 13.65% | 1.05x | 1.23x | $8.56 Million |
| 2015 | 16.95% | 15.03% | 0.92x | 1.22x | $9.06 Million |
| 2016 | 13.62% | 10.58% | 0.72x | 1.79x | $5.20 Million |
| 2017 | 16.24% | 12.22% | 0.80x | 1.67x | $9.85 Million |
| 2018 | 5.89% | 4.78% | 0.68x | 1.81x | $-6.25 Million |
| 2019 | 9.08% | 6.52% | 0.74x | 1.88x | $-1.46 Million |
| 2020 | 14.59% | 10.07% | 0.75x | 1.92x | $7.92 Million |
| 2021 | 19.42% | 13.91% | 0.78x | 1.79x | $19.38 Million |
| 2022 | 12.98% | 10.64% | 0.69x | 1.77x | $6.70 Million |
| 2023 | 5.60% | 4.99% | 0.56x | 2.00x | $-10.27 Million |
| 2024 | 6.61% | 6.22% | 0.58x | 1.84x | $-8.23 Million |
Industry Comparison
This section compares Stratec SE's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $498,972,584
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stratec SE (STSEY) | $240.08 Million | 9947.18% | 0.80x | $48.57 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-2.23 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $187.53 Billion |
| Acarix AB (publ) (ACIXF) | $51.88 Million | -150.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $3.82 Million |
| Adm Tronics Unltd (ADMT) | $644.00K | 0.00% | 0.66x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $732.88K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $916.00 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $8.41 Million |